Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7‐day triple therapy with regular proton pump inhibitor dosage
Authors:
- 31 July 2008
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 23 (8pt1) , 1287-1291
Abstract
Background and Aim: Proton pump inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole‐ or esomeprazole‐based triple therapy.Methods: A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing.Results: The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively.Conclusion: The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole‐based triple therapy.Keywords
This publication has 37 references indexed in Scilit:
- Second‐Line Treatment for Helicobacter pylori Infection: 10‐day Moxifloxacin‐Based Triple Therapy versus 2‐week Quadruple TherapyHelicobacter, 2007
- Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patientsJournal of Gastroenterology and Hepatology, 2007
- Effect ofMDR1C3435T polymorphism on cure rates ofHelicobacter pyloriinfection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation toCYP 2C19 genotypes and 23S rRNA genotypes ofH. pyloriAlimentary Pharmacology & Therapeutics, 2007
- Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitisJournal of Gastroenterology and Hepatology, 2007
- Treatment of Helicobacter pylori InfectionHelicobacter, 2006
- Influence of CYP2C19 Polymorphism and Helicobacter pylori Genotype Determined From Gastric Tissue Samples on Response to Triple Therapy for H pylori InfectionClinical Gastroenterology and Hepatology, 2005
- Cytochrome P450 Genotyping by Multiplexed Real-Time DNA Sequencing with Pyrosequencing™ TechnologyASSAY and Drug Development Technologies, 2002
- Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotypeJournal of Gastroenterology and Hepatology, 2002
- Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populationsPharmacogenetics, 1997
- Twenty‐four‐hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.Alimentary Pharmacology & Therapeutics, 1996